Missana Liliana R, Jammal María V
Oral Pathology Department, Laboratory of Experimental Pathology and Tissue Engineering, Dental School, Tucumán University, Tucumán, Argentina; Laboratory of Experimental Pathology and Tissue Engineering, PROIMI-Biotechnology (Pilot Plant for Microbial Industrial Processes and Biotechnology), CONICET, Tucumán, Argentina.
J Biomed Mater Res A. 2014 Dec;102(12):4358-64. doi: 10.1002/jbm.a.35114. Epub 2014 Feb 24.
Recombinant Human Parathyroid Hormone (rhPTH 1-34) administration is an effective treatment to improve bone mass in osteoporosis. The aim of this study was to develop a Tissue Engeenering Tool for bone regeneration. We evaluated the efficacy of a freeze dried rhPTH membrane in calvarial critical size defect (CSD). Forty-four Wistar female rats (body weight 150 ± 50 g) with CSD (5 mm) were divided into four groups: group 1: rhPTH membrane (rhPTHm); group 2: atelocollagen membrane (Cm); group 3: rhPTH and atelocollagen I (CrhPTHm); group 4: without any treatment (CG). All samples were evaluated on the 1st, 3rd, and 6th weeks (weeks) post-surgery by soft X-ray, histological and histometric studies. Soft X-ray results showed a radiolucent image with many irregular radiopaque areas. Histologically, rhPTHm was replaced by reticular bone (7%) since 3rd week, and lamellar bone ossicles (30%) at 6th week. Cm showed bone formation like composite bone type on week 1st, 3rd, and 6th (2%, 44%, and 41%, respectively). With CrhPTHm, bone formation was observed in all periods (2.4%, 48%, and 53%), showing statistical difference with CG in the 3rd and 6th wks (p = 0.03 and 0.01). Our results demonstrated the effectiveness of a new biomaterial called CrhPTHm because its ability to regenerate calvarial CSD. Moreover, the membrane represents a new local intermittent delivery system allowing rhPTH slow release.
重组人甲状旁腺激素（rhPTH 1-34）给药是改善骨质疏松症骨量的一种有效治疗方法。本研究的目的是开发一种用于骨再生的组织工程工具。我们评估了冻干rhPTH膜在颅骨临界尺寸缺损（CSD）中的疗效。将44只患有5mm CSD的Wistar雌性大鼠（体重150±50g）分为四组：第1组：rhPTH膜（rhPTHm）；第2组：去端胶原蛋白膜（Cm）；第3组：rhPTH与I型去端胶原蛋白（CrhPTHm）；第4组：不进行任何治疗（CG）。在术后第1、3和6周通过软X线、组织学和组织计量学研究对所有样本进行评估。软X线结果显示为具有许多不规则不透光区域的透光图像。组织学上，rhPTHm自第3周起被网状骨替代（7%），第6周时被板层骨小骨替代（30%）。Cm在第1、3和6周显示出如复合骨类型的骨形成（分别为2%、44%和41%）。对于CrhPTHm，在所有时期均观察到骨形成（2.4%、48%和53%），在第3和6周与CG相比有统计学差异（p = 0.03和0.01）。我们的结果证明了一种名为CrhPTHm的新型生物材料的有效性，因为它具有再生颅骨CSD的能力。此外，该膜代表了一种新的局部间歇性给药系统，可使rhPTH缓慢释放。
